Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Open accessThe DOI matches its Crossref record; 475 of the 479 references it cites were found in a registry or an index.
Abstract
There has been an alarming increase in the prevalence of obesity in people with type 1 diabetes in recent years. Although obesity has long been recognized as a major risk factor for the development of type 2 diabetes and a catalyst for complications, much less is known about the role of obesity in the initiation and pathogenesis of type 1 diabetes. Emerging evidence suggests that obesity contributes to insulin resistance, dyslipidemia, and cardiometabolic complications in type 1 diabetes. Unique therapeutic strategies may be required to address these comorbidities within the context of intensive insulin therapy, which promotes weight gain. There is an urgent need for clinical guidelines for the prevention and management of obesity in type 1 diabetes. The development of these recommendations will require a transdisciplinary research strategy addressing metabolism, molecular mechanisms, lifestyle, neuropsychology, and novel therapeutics. In this review, the prevalence, clinical impact, energy balance physiology, and potential mechanisms of obesity in type 1 diabetes are described, with a special focus on the substantial gaps in knowledge in this field. Our goal is to provide a framework for the evidence base needed to develop type 1 diabetes-specific weight management recommendations that account for the competing outcomes of glycemic control and weight management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Self-citationMootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785
Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823
Research works printed but not linked: 1
- Saudek, 1996, Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial, JAMA, 276, 1322, 10.1001/jama.1996.03540160044031 · DOI · Paper page
Cited by
Items 201–273 of 273
Kelly, J., Steenkamp, D., Brouillard, E., & Wolpert, H. A. (2025) · Diabetic Medicine · doi:10.1111/dme.70031 · Cited by 2
Gillon‐Keren, M., Propper‐Lewinsohn, T., David, M., Fayman, G., Phillip, M., & Oron, T. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112400 · Cited by 2
Obesity in Type 1 Diabetes Mellitus
Kalkan, G. E., & Özcan, B. A. (2023) · Wiley eBooks · doi:10.1002/9781119983347.ch9 · Cited by 2
Saiyed, M., Saboo, B., Pancholi, M., Saraf, V., & Shah, M. (2022) · Journal of Diabetology · doi:10.4103/jod.jod_101_21 · Cited by 1
Immuno-Metabolic Interplay in Health and Disease
Agrahari, R., Mohapatra, S., Kumar, K. S., Mohanty, D., Kumar, R. K., & Merugu, R. (2024) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-97-5508-0_11 · Cited by 5
Warnick, J. L., Darling, K. E., Maskey, S., Topor, L. S., Fox, K., Olson, K. L., & Jelalian, E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100194 · Cited by 1
“Treatment of one hypoglycemic episode per day can result in a 6-pound weight gain over a year [13].”
Lipid Transporter ABCA1 in Diabetic Polyneuropathy: Potential Mediation by Circulating Metabolites
Cao, Y. H., Pan, Y., Yan, Y., Yao, Y., Lu, S., Gei, L., Jiang, W., Zeng, W., & Chen, D. (2025) · Journal of Pain Research · doi:10.2147/jpr.s535866 · Cited by 1
“…syndrome (MetS) and its components, especially dyslipidemia, which frequently coexist with diabetes and its associated complications, to DPN. 26,27 It has been demonstrated that the presence of saturated fatty acid (SFA) palmitate and other forms of dyslipidemia can lead to a reduction in…”
Koning, S. J., Dekker, P., Birnie, E., van den Heuvel, T. R. A., Castañeda, J., van Beers, K. A. J., Veeze, H. J., Cohen, O., & Aanstoot, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70410 · Cited by 1
Kağızmanlı, G. A., Erden, D., Demir, K., Böber, E., & Abacı, A. (2025) · Endocrine · doi:10.1007/s12020-025-04477-4 · Cited by 1
Managing Obesity in Individuals with Cardiovascular Disease: Are We Missing the Obvious?
Gao, M., Kurala, T. S., & Ajjan, R. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.53 · Cited by 1
“66 While several studies have demonstrated that GLP-1RA use can reduce body weight and insulin dose requirements in this population, the absence of vascular outcome studies has limited the use of these agents in T1D.”
Uti, D. E., Egbung, J. E., Alum, E. U., Bawa, I., Agada, S. A., Ogbu, C. O., & Ugwu, O. P.-C. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100712 · Cited by 3
MASLD and Atherosclerosis in Patients with Type 2 Diabetes Mellitus: A Systematic Review
(Diaconu), C.-T. V., Reurean‐Pintilei, D., Chitu, M.-C., Salmen, T., Stoian, A. P., & Guja, C. (2026) · Medicina · doi:10.3390/medicina62050919 · Cited by 1
“In adults with T1D, the prevalence of MASLD/NAFLD ranges from 4.7 to 52% [37–39].”
InfluentialNgcobo, N. N., & Sibiya, N. H. (2026) · Pathophysiology · doi:10.3390/pathophysiology33030048 · Cited by 1
“Preclinical studies using high-fat, high-carbohydrate diets suggest that glucotoxicity and lipotoxicity may contribute to β -cell fragility, and elevated free fatty acids may promote inflammatory signaling [61,65,66].”
Robino, A., Tornese, G., Aldegheri, L., Franceschi, R., Mozzillo, E., Candia, F. D., Morosini, C., Zanfardino, A., Delvecchio, M., Bombaci, B., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03038-4 · Cited by 1
SOBREPESO Y OBESIDAD EN ADULTOS CON DIABETES MELLITUS TIPO 1
Rodríguez, M., Cicchitti, A., Bertona, C., González, J., Carrasco, N., Barrera, L., David, R., Romero, L., Biliato, L., & Trinajstic, E. M. (2019) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v53i3.171 · Cited by 3
Penna, G. L. (2021) · The Journal of AMD · doi:10.36171/jamd20.23.4.13 · Cited by 1
Beyond Two Cultures: Cultural Infrastructure for Data-driven Decision Support
Freeman, N. L. B., Sperger, J., El-Zaatari, H., Kahkoska, A. R., Lu, M., Valancius, M., Virkud, A., Zikry, T. M., & Kosorok, M. R. (2021) · Observational Studies · doi:10.1353/obs.2021.0024 · Cited by 2
Bryant, B. L., Wang, C. H., & Monaghan, M. C. (2023) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-023-09936-6 · Cited by 1
“…health outcomes, most AYAs with T1D do not achieve the minimum exercise recommendations, partially due to the added challenge of keeping blood glucose values in target range during physical activity and avoiding hypoglycemia (Corbin et al., 2018; Driscoll et al., 2017; Zaharieva et al., 2020).”
BackgroundPorcu, L. (2023) · The Journal of AMD · doi:10.36171/jamd23.26.1.4 · Cited by 1
Salehi, S., Mehrpour, S., Koohmanaee, S., Maleknejad, S., Esfandiari, M. A., Maroufizadeh, S., Dalili, S., & Rad, A. H. (2023) · Hepatitis Monthly · doi:10.5812/hepatmon-135941 · Cited by 1
“NAFLD associated with insulin resistance, and its prevalence is currently increasing in T1DM (13, 14).”
BackgroundProvision of continuous subcutaneous insulin infusion to type 1 diabetes ‘frequent flyers’
Amato, L. A., Kalolo, R., Yu, W., & Simmons, D. S. (2023) · Internal Medicine Journal · doi:10.1111/imj.16213 · Cited by 1
Eating behaviors and estimated body fat percentage among adolescents with type 1 diabetes
Tran, T., IGUDESMAN, D. A., Burger, K. S., Crandell, J., Maahs, D. M., Seid, M., & Mayer‐Davis, E. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111070 · Cited by 1
Self-citationBariatric Surgery: Can It Perform Benefits or Risks?
Mostafa, T. A.-H., Abdel-Hameed, A. M., & Ahmed, S. A.-K. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1006090 · Cited by 1
Understanding the Genetic and Environmental Factors Contributing to Type 1 Diabetes
Khan, S., Usama, M., Ali, R., Gulfam, M., Haider, K., & Asghar, R. (2024) · Innovative Research in Applied Biological and Chemical Sciences · doi:10.62497/irabcs.2024.59 · Cited by 1
Cipponeri, E., Tarsitano, M. G., Falbo, E., & Conte, C. (2025) · Discover Endocrinology and Metabolism · doi:10.1007/s44417-025-00010-3 · Cited by 1
“The growing prevalence of overweight/obesity and related metabolic alterations [13] in T1D highlights a critical area for investigation as it has implications for disease management and the potential for targeted interventions.”
Can Real World Evidence on Body Mass Index Trajectories Inform Clinical Practice?
Addala, A., & Maahs, D. M. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.06.062
Self-citationOptimizing Diet in Patients with Diabetes
Shah, M. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch10
Mlotshwa, C. R. N., Burger, J. R., Vorster, M., Rakumakoe, D. M., & Cockeran, M. (2021) · Current Drug Safety · doi:10.2174/1574886316666211108103301
Metabolic and cardiovascular risk factors associated with type 1 Diabetes Mellitus in pediatric age
Araújo, M., & Correia, C. C. (2022) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/ar210013
Avery, A. (2021) · Archives of Diabetes & Obesity · doi:10.32474/ado.2021.03.000172
“The prevalence of obesity in people with T1D is increasing, driven by the increase in its prevalence in the general population and the intensive therapeutic approaches to the management of hyperglycaemia in T1D [6].”
BackgroundClinical practice guidelines update 2022: Focus on diabetes
Cornell, S. A. (2022) · Pharmacy Today · doi:10.1016/j.ptdy.2022.05.022
Elhabashy, S. A., Elbarbary, N. S., Hassan, A. A., & Thabet, R. A. (2022) · Research Square · doi:10.21203/rs.3.rs-2011231/v1
Guimarães, J. P. T. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2021.tde-04052022-144336
Gilbert, J. D., Balicsak, D., Kettle, S., Lewis, V. S., Medel, N., Montgomery, C. W., & Hagen, L. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.02.001
Berk, K. A., van Damme, I., & Feskens, E. J. M. (2023) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2868-0_26
Othman, L. B., Alamri, A., Assiri, Y. M., & Alzahrani, F. (2023) · Medical Science · doi:10.54905/disssi/v27i136/e277ms3042
“Increased Body Mass Index (BMI) in T1D patients is linked with higher cardiometabolic risk and rapid chronic complication progression compared to their lean counterparts (Corbin et al., 2018).”
BackgroundMunir, K. M., & Davis, S. N. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2241354
Iklé, J. M., Addala, A., & Maahs, D. M. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch69
Self-citationHakeem, R., Rashid, T., & Sheikh, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22106-4.00004-8
A Current Review on Diabetes Mellitus Induced Gut Microbiota and Histological Changes
Rağbetli, M. Ç., & Keskin, S. (2023) · doi:10.69860/nobel.9786053359104.2
Special Therapeutic Situations
Drobycki, N., Gupta, O., Choudhary, A., Mirfakhraee, S., Litty, A., Meneghini, L., & Jacob, N. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch04
Mendes, R. C. M., Albuquerque, N. V., Montenegro, R. M., Martins, M. Y. P. T., Porto, C. M. T. D. S., Nunes, A., Maia, C. S. C., & Araújo, S. T. (2022) · Nutrición clínica y dietética hospitalaria/Nutrición clínica, dietética hospitalaria · doi:10.12873/421machado
Wolska, M., Kaziród-Wolski, K., Sielski, J. K., Malinowski, K. P., Hawranek, M., & Siudak, Z. (2025) · Medical Studies · doi:10.5114/ms.2025.152572
Hidalgo, K. A. M., & Huamán-Varillas, G. J. (2025) · Universidad Peruana de Ciencias Aplicadas (UPC) · doi:10.19083/tesis/684416
Doğruel, D., Turan, İ., Gürbüz, F., Mengen, E., Celiloğlu, C., & Yüksel, B. (2025) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.1712723
Onyejose, K. N., Ndep, A. O., Azubuike, P. C., Akinreni, T., Ogbonna, C. K., George, A. S., Timothy, P. N., & Okon, A. J. (2025) · Research Square · doi:10.21203/rs.3.rs-8253163/v1
Jiang, Y., Zhang, W., Wei, M., Yin, D., Tang, Y., Jia, W., Wang, C., Guo, J., Li, A., & Gong, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25347010
INGESTIVE BEHAVIORS AND BODY FAT PERCENTAGE AMONG ADOLESCENTS WITH TYPE 1 DIABETES
Tran, T. V. (2023) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/mqf3-k729
Ho, J. (2025) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/ztwc-g564
Schroeder, A. E. (2022) · K-State Research Exchange (Kansas State University)
Type 1 diabetes presenting initially as type 2 diabetes which remitted with lifestyle change
Ali, A., Macklin, A., & Nicholls, A. (2025) · British Journal of Diabetes · doi:10.15277/bjd.2025.489
Krzyżowska, S. (n.d.) · Jagiellonian University Repository (Jagiellonian University)
Obesity and overweight‐related differences in cardiometabolic risk factors in type 1 diabetes
Syed, A. S., Arani, G., Macwan, S. A., Koška, J., Zhou, J. Y., Miller, D. R., & Reaven, P. D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70329
“4,6 Use of AOMs in overweight and obese T1D patients was rare and this was consistent across age groups.”
Wang, Y., Zhang, H., Li, Y., Guo, F., Li, J. Q., Wang, W., & Zhang, W. (2026) · Frontiers in Veterinary Science · doi:10.3389/fvets.2026.1737345
Kaddour, N. (2025) · Dépôt Institutionnel de lUniversité de Tlemcen
Mitchell, S., Patwardhan, K., Lucocq, J. E., Geropoulos, G., Lamb, P., Ghanem, O. M., Stimson, R. H., & Robertson, A. G. (2026) · Diabetic Medicine · doi:10.1111/dme.70305
周, 玮. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641306
Assessing the role of the transcription factor E2F1 in β-cells identity, function and plasticity
Friano, M. E. (2021) · theses.fr (ABES) · doi:10.70675/93ae4c67z2303z493aza0d5z5ae0eb9ffee4
Oliver-Rose, C., Lagera, L. M., Cooper, A., Hofman, P. L., Derraik, J. G. B., & Anderson, Y. C. (2026) · Pediatric Diabetes · doi:10.1155/pedi/4106777
“Research on overweight and obesity in young people with T1D is critical, as this combination can magnify cardiometabolic risk and exacerbate mental health issues [10, 14, 15].”
InfluentialMarqueurs diagnostiques du diabète de type 1 en 2026 et stratégie de dépistage précoce
Berger, A.-E., & Gonçalves, D. (2026) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(26)76659-4
Ni, H., SNAITH, J. R., & Greenfield, J. R. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.001
Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 1 Diabetes
Buros‐Stein, A., PAULEY, M. E., & Snell‐Bergeon, J. K. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.003
Wright, E. E., Wang, C. C. L., Novak, L. M., & Shubrook, J. H. (2026) · Postgraduate Medicine · doi:10.1080/00325481.2026.2672192
“However, because of the rising prevalence of overweight and obesity, individuals with adult-presenting T1D are increasingly likely to present with higher BMI, metabolic dysregulation, and some degree of dyslipidemia at diagnosis [32,33].”
Şahin, M. F., Kiyici, S. K., Sığırlı, D., & Karaca, S. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02401-z
“Hormonal and metabolic alterations associated with T1DM, including changes related to glycemic control, nutritional status, and insulin therapy, further contribute to the heterogeneity of ghrelin responses in this population [21].”
InfluentialObesity in Adults with Type 1 Diabetes Mellitus
Batman, A., Sulu, C., YAZICI, D., Boyle, L., McGowan, B. M., & Yumuk, V. (2026) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes26001
“7,34 Enlarged adipocytes release pro-inflammatory cytokines, such as tumor necrosis factor-α, interleukin 6 (IL-6), and IL-1β, and attract immune cells into adipose depots.”
Overweight and obesity in youth with type 1 diabetes
VELASQUEZ, H. J., Huang, X., Minard, C., Siller, A. F., Gupta, R. M., Faruqi, J., Hoyos-Martínez, A., Sisley, S. R., & REDONDO, M. J. (2026) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2026-0168
“Individuals with T1D and obesity experience increased insulin resistance and thus, high insulin requirements, have a greater cardiometabolic risk, and an increased risk of developing chronic complications when compared to normal-weight individuals with T1D [5].”
Understanding Diabetic Neuropathy: From Pathophysiology to Therapeutic Targets
Eid, S., Rumora, A. E., Koubek, E. J., & Feldman, E. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00021-4
Targeting kidney disease in type 1 diabetes: progress and promise
Muskiet, M. H. A., & Cherney, D. Z. I. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2714265
“A key contributor is the dramatic rise in obesity among individuals with T1D, which has increased nearly tenfold over the past five decades [20] and now affects ~28% of adults (range, 12.0– 52.4%), with a 2017 survey showing that more than one-third of adolescents have overweight or obesity,…”
InfluentialSaavedra, D., Mittal, R., Blaschke, C. E., Tondin, A. R., Añé-Kourí, A. L., Lage, A., Frasca, D., & Skyler, J. S. (2026) · Diabetes · doi:10.2337/db26-0159
Curcumin: Bioavailability and therapeutic potential in metabolic disorders and chronic diseases
Ashraf, H., Ul‐Haq, I., Yıkmış, S., Abdi, G., & Aadil, R. M. (2026) · Food and Humanity · doi:10.1016/j.foohum.2026.101437
Zhen, X. M., Ross, G. P., Gauld, A., Sweeting, A., Nettel‐Aguirre, A., Noonan, S., Constantino, M., Harding, A., Mackie, A., Chatila, H., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70440
“26 Our recent fi ndings indicate that pregnancies affected by T1DM have higher risk pro fi les compared to those with T2DM, despite the greater apparent sociodemographic disadvantage, lower measures of pregnancy preparedness, and higher rates of obesity seen amongst the women with T2DM.”
Decoding inflammation to target hybrid diabetes phenotypes
Rossi, G., Terranegra, A., Lunati, M. E., Pastore, I., CANOVA, L. P., Bucciarelli, L. G., Cimino, V., Loretelli, C., Nasr, M. B., Fiorina, P., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1922969
“mechanisms behind obesity and insulin resistance in T1D include genetics, epigenetics, enteroendocrine hormones, microbiome, and environmental factors, with effects on multiple organs (3, 4).”
Singh, D. P., Kumar, P., Singh, I., Malakar, D., & Packirisamy, G. (2026) · ACS Nutrition Science · doi:10.1021/acsnutrsci.6c00005
Metadata
- Authors
- Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON)
- Affiliations
- Translational Research Institute for Metabolism and Diabetes (US)
- University of Colorado Denver (US)
- Stanford Medicine (US)
- Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
- Corresponding author
- Corbin, Karen D
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2018-07-27
- Volume
- 39
- Issue
- 5
- Pages
- 629-663
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2884950815
- Cited by
- 262
- References
- 479
- Citations by year
- 2026: 28 · 2025: 35 · 2024: 40 · 2023: 33 · 2022: 43 · 2021: 41 · 2020: 23 · 2019: 14 · 2018: 5
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- North Carolina State University
- Bigfoot Biomedical
- Insulet Corporation
- Orexigen Therapeutics
- Five Prime Therapeutics
- Dexcom
- Zafgen
- NGM Biopharmaceuticals
- York University
- Eisai
- Novo Nordisk
- University of North Carolina at Chapel Hill
- University of Colorado Denver
- Abbott Diabetes Care
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, type 1 diabetes, insulin resistance, dyslipidemia, cardiometabolic complications, intensive insulin therapy, weight gain, energy balance, obesity pathogenesis, weight management, glycemic control, obesity prevalence
- MeSH terms
- Diabetes Mellitus, Type 1, Humans, Insulin Resistance, Life Style, Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.